Fidaxomicin monotherapy versus standard therapy combined with bezlotoxumab for treating patients with Clostridioides difficile infection at high risk of recurrence : a matched cohort study
© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: Both fidaxomicin and bezlotoxumab (used in combination with an antibiotic against Clostridioides difficile) achieve reductions in recurrence rates of C. difficile infection (CDI). However, the two strategies have never been compared.
METHODS: Data from two retrospective cohorts of 'real-life' use of fidaxomicin and bezlotoxumab in combination with a standard anti-C. difficile antibiotic were used to compare the rates of recurrence of both strategies. Since the two cohorts were not identical, we used a propensity score analysis.
RESULTS: Three hundred and two patients were included: 244 in the fidaxomicin cohort and 78 in the bezlotoxumab cohort. A history of renal failure or immunosuppression was more frequent in patients receiving bezlotoxumab (39.7% and 66.7% versus 26.6% and 38.9%; P = 0.03 and P < 0.001, respectively), but the severity and number of previous CDI episodes were similar in both cohorts. We observed that 19.3% of the patients in the fidaxomicin cohort experienced recurrence, compared with 14.1% in the bezlotoxumab cohort (OR 1.45; 95% CI 0.71-2.96; P = 0.29) but the difference remained non-significant after propensity score matching using previously defined variables (OR 1.24; 95% CI 0.50-3.07; P = 0.64). Moreover, the multivariate analysis did not show differences depending on the drug used.
CONCLUSIONS: We observed that fidaxomicin and bezlotoxumab are prescribed in similar clinical scenarios, although those treated with bezlotoxumab have greater comorbidity. The proportion of recurrences was numerically lower in those treated with bezlotoxumab, although the propensity analysis did not find significant differences between the two drugs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:77 |
|---|---|
| Enthalten in: |
The Journal of antimicrobial chemotherapy - 77(2022), 7 vom: 29. Juni, Seite 1996-2002 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Escudero-Sanchez, Rosa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4H5YMK1H2E |
|---|
| Anmerkungen: |
Date Completed 01.07.2022 Date Revised 06.07.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/jac/dkac106 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339328193 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339328193 | ||
| 003 | DE-627 | ||
| 005 | 20231226002644.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jac/dkac106 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1131.xml |
| 035 | |a (DE-627)NLM339328193 | ||
| 035 | |a (NLM)35403189 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Escudero-Sanchez, Rosa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fidaxomicin monotherapy versus standard therapy combined with bezlotoxumab for treating patients with Clostridioides difficile infection at high risk of recurrence |b a matched cohort study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.07.2022 | ||
| 500 | |a Date Revised 06.07.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Both fidaxomicin and bezlotoxumab (used in combination with an antibiotic against Clostridioides difficile) achieve reductions in recurrence rates of C. difficile infection (CDI). However, the two strategies have never been compared | ||
| 520 | |a METHODS: Data from two retrospective cohorts of 'real-life' use of fidaxomicin and bezlotoxumab in combination with a standard anti-C. difficile antibiotic were used to compare the rates of recurrence of both strategies. Since the two cohorts were not identical, we used a propensity score analysis | ||
| 520 | |a RESULTS: Three hundred and two patients were included: 244 in the fidaxomicin cohort and 78 in the bezlotoxumab cohort. A history of renal failure or immunosuppression was more frequent in patients receiving bezlotoxumab (39.7% and 66.7% versus 26.6% and 38.9%; P = 0.03 and P < 0.001, respectively), but the severity and number of previous CDI episodes were similar in both cohorts. We observed that 19.3% of the patients in the fidaxomicin cohort experienced recurrence, compared with 14.1% in the bezlotoxumab cohort (OR 1.45; 95% CI 0.71-2.96; P = 0.29) but the difference remained non-significant after propensity score matching using previously defined variables (OR 1.24; 95% CI 0.50-3.07; P = 0.64). Moreover, the multivariate analysis did not show differences depending on the drug used | ||
| 520 | |a CONCLUSIONS: We observed that fidaxomicin and bezlotoxumab are prescribed in similar clinical scenarios, although those treated with bezlotoxumab have greater comorbidity. The proportion of recurrences was numerically lower in those treated with bezlotoxumab, although the propensity analysis did not find significant differences between the two drugs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Broadly Neutralizing Antibodies |2 NLM | |
| 650 | 7 | |a bezlotoxumab |2 NLM | |
| 650 | 7 | |a 4H5YMK1H2E |2 NLM | |
| 650 | 7 | |a Vancomycin |2 NLM | |
| 650 | 7 | |a 6Q205EH1VU |2 NLM | |
| 650 | 7 | |a Fidaxomicin |2 NLM | |
| 650 | 7 | |a Z5N076G8YQ |2 NLM | |
| 700 | 1 | |a Muriel García, Alfonso |e verfasserin |4 aut | |
| 700 | 1 | |a García Fernández, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Valencia Alijo, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Tasias Pitarch, Mariona |e verfasserin |4 aut | |
| 700 | 1 | |a Merino De Lucas, Esperanza |e verfasserin |4 aut | |
| 700 | 1 | |a Gutierrez Rojas, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos Martínez, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Salavert Lletí, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Giner, Livia |e verfasserin |4 aut | |
| 700 | 1 | |a Ruíz Ruigomez, María |e verfasserin |4 aut | |
| 700 | 1 | |a García Basas, Lorena |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández Fradejas, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Olmedo Sampedrio, María |e verfasserin |4 aut | |
| 700 | 1 | |a Cano Yuste, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Díaz Pollán, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez Hernández, María Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Martín Segarra, Oriol |e verfasserin |4 aut | |
| 700 | 1 | |a Sáez Bejar, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Armiñanzas Castillo, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Gutiérrez, Belén |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Pardo, Dolors |e verfasserin |4 aut | |
| 700 | 1 | |a De La Torre Cisneros, Julián |e verfasserin |4 aut | |
| 700 | 1 | |a López Medrano, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Cobo Reinoso, Javier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of antimicrobial chemotherapy |d 1981 |g 77(2022), 7 vom: 29. Juni, Seite 1996-2002 |w (DE-627)NLM000017701 |x 1460-2091 |7 nnns |
| 773 | 1 | 8 | |g volume:77 |g year:2022 |g number:7 |g day:29 |g month:06 |g pages:1996-2002 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jac/dkac106 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 77 |j 2022 |e 7 |b 29 |c 06 |h 1996-2002 | ||